Prostate cancer drug market 'worth $9.1bn by 2021'

Decision Resources' latest report looks at the prostate cancer drug market between now and 2021.

The market for prostate cancer drugs will more than double between 2011 and 2021, new research suggests.
Decision Resources' Pharmacor Prostate Cancer advisory service looked at the prostate cancer drug market's potential in the key markets of the US, France, Germany, Italy, Spain, the UK and Japan.

It estimates that the market will grow from $4.1 billion in 2011 to $9.1 billion in 2021.

One of the key factors fuelling this significant growth will be increasing uptake of the premium-priced drug Xtandi (Medivation/Astellas Pharma), the research and advisory firm said.

The androgen receptor signalling inhibitor is expected to compete with Zytiga, which was launched in 2011.
"We expect Xtandi to emerge as the patient share leader for chemotherapy-naive mCRPC and, beginning in 2016, it will become the top-selling agent in the prostate cancer market through 2021," said Decision Resources analyst Dr Rachel Webster.

"We forecast Xtandi will garner sales of $2.2 billion by 2021."

The report also suggests that the number of men with metastatic prostate cancer will fall by 25 per cent over the next 20 years, thanks to a recent decline in the number of men being diagnosed with prostate cancer and more effective treatments.